hapabapa
Veru Inc. (NASDAQ:VERU), a biopharma targeting cancer, added 19% pre-market Monday as the company is set to face an FDA Advisory Committee meeting this week regarding its marketing application for the oral COVID-19 therapy sabizabulin.
The regulator has